| Followers | 65 |
| Posts | 10174 |
| Boards Moderated | 0 |
| Alias Born | 03/29/2015 |
Saturday, September 02, 2023 1:58:09 PM
Smallpox is a very different disease than cancer and a vaccine for it could be fabricated using 18th century technology though that vaccine could be dangerous or even lethal to some patients. Over time the Smallpox vaccine was improved. Also Smallpox vaccines are given to healthy patients in advance to prevent illness.
GBM has a much higher degree of lethality and while smallpox is essentially the same disease from patient to patient, for GBM each vaccine must get a custom-tailored vaccine and making it requires late 20th and early 20th century technology. DCVax-L is given to already sick patients whose immune systems are damaged by radiation and chemo.
These facts make GBM very hard to deal with compared to smallpox.
The fact that GBM is much harder to address means that the results we get with it will be less impressive though still worth it. By investing in rolling out DCVax-L we will be able to develop better versions just as the Smallpox vaccine was improved over decades and centuries.
GBM has a much higher degree of lethality and while smallpox is essentially the same disease from patient to patient, for GBM each vaccine must get a custom-tailored vaccine and making it requires late 20th and early 20th century technology. DCVax-L is given to already sick patients whose immune systems are damaged by radiation and chemo.
These facts make GBM very hard to deal with compared to smallpox.
The fact that GBM is much harder to address means that the results we get with it will be less impressive though still worth it. By investing in rolling out DCVax-L we will be able to develop better versions just as the Smallpox vaccine was improved over decades and centuries.
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
